{
    "clinical_study": {
        "@rank": "159713", 
        "acronym": "AGC-HER2CTC", 
        "arm_group": {
            "arm_group_label": "chemotheropy", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "To identify the correlation of HER2 expression in tissue and peripheral CTC. to identify the\n      HER2 expression in CTCs with clinical prognosis in advanced/metastatic gastric cancer.\n\n      Confirm the presence of CTCs are sensitive for monitoring response to chemotherapy."
        }, 
        "brief_title": "HER2 Positive CTC in Advanced Gastric Cancer", 
        "completion_date": {
            "#text": "June 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "HER2 Positive Advanced Gastric Cancer", 
        "condition_browse": {
            "mesh_term": "Stomach Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Having signed informed consent\n\n          -  Age\u2265 18 years old\n\n          -  HER2 overexpression confirmed by IHC or ISH (IHC 3+,or IHC2+/ISH+)\n\n          -  Histologically confirmed gastric adenocarcinoma\n\n          -  Unresectable recurrent or metastatic disease\n\n          -  Previous neo-adjuvant or adjuvant treatment for gastric cancer, if applicable, more\n             than 6 months\n\n          -  Measurable disease according to the RECIST criteria\n\n          -  Karnofsky performance status \u226570\n\n          -  Life expectancy of \u22653 month\n\n          -  No prior radiotherapy except radiotherapy at non-target lesion of the study more than\n             4 weeks\n\n          -  ALT and AST<2.5 times ULN (\u22645 times ULN in patients with liver metastases)\n\n          -  Serum albumin level \u22653.0g/dL\n\n          -  Serum AKP < 2.5 times ULN\n\n          -  Serum creatinine <ULN, and CCr < 60ml/min\n\n          -  Bilirubin level < 1.5 ULN\n\n          -  WBC>3,000/mm3, absolute neutrophil count \u22652000/mm3, platelet>100,000/mm3, Hb>9g/dl\n\n        Exclusion Criteria:\n\n          -  Previous systemic therapy for metastatic gastric cancer\n\n          -  Surgery (excluding diagnostic biopsy) within 4 weeks prior to study entry\n             Contraindications of nuclear magnetic resonance image such as fitment of cardiac\n             pacemaker , nerve stimulator, or aneurysm clip, and metallic foreign body in eye ball\n             and so on.\n\n          -  Allergic constitution or allergic history to protium biologic product or any\n             investigating agents.\n\n          -  Severe heart disease or such history as recorded congestive heart failure,\n             uncontrolled cardiac arrhythmia, angina pectoris needing medication, cardiac valve\n             disease, severe abnormal ECG findings, cardiac infarction , or retractable\n             hypertension.\n\n          -  Pregnancy or lactation period\n\n          -  Other previous malignancy within 5 year, except non-melanoma skin cancer\n\n          -  Legal incapacity"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 29, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01847794", 
            "org_study_id": "CGOG5002"
        }, 
        "intervention": {
            "arm_group_label": "chemotheropy", 
            "description": "Collect peripheral blood sample of 50 gastric cancer patients pre-chemotherapy and post two cycles of chemotherapy(response evaluation).\nBlood samples will be transferred to central lab to detect HER2 positive CTCs by Cellsearch epithelial kit.\nTumor response evaluation will be performed after two cycles of chemotherapy by CT/MRI based on RECIST. Clinical data, including tumor stage, metastastic organ, chemotherapy regimen, objective response, progression free survival, overall survival, etc, will be collected according to study protocol.", 
            "intervention_name": "Cell Search\u00ae CTC epithelial kit", 
            "intervention_type": "Device"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 2, 2013", 
        "location": {
            "contact": {
                "email": "zhangxtxx@gmail.com", 
                "last_name": "xiaotian zhang, MD. PhD", 
                "phone": "(86)10-88196561"
            }, 
            "contact_backup": {
                "email": "gongjifang@gmail.com", 
                "last_name": "jifang gong, MD. PhD", 
                "phone": "(86)10-88196561"
            }, 
            "facility": {
                "address": {
                    "city": "Beijing", 
                    "country": "China", 
                    "state": "Beijing", 
                    "zip": "100142"
                }, 
                "name": "Peking cancer hospital"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "1", 
        "official_title": "Clinical Significance of HER2 Positive Circulating Tumor Cells(CTCs) in the Peripheral Blood of Patients With Advanced Gastric Cancer", 
        "overall_contact": {
            "email": "lin100@medmail.com.cn", 
            "last_name": "lin shen, MD. PhD", 
            "phone": "(86)10-88196175"
        }, 
        "overall_official": {
            "affiliation": "Peking University", 
            "last_name": "Lin Shen, MD. PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "HER2 positive CTC", 
            "safety_issue": "No", 
            "time_frame": "2 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01847794"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Peking University", 
            "investigator_full_name": "Shen Lin", 
            "investigator_title": "Director of GI oncology", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "measure": "clinical significance of HER 2 positive CTC", 
            "safety_issue": "No", 
            "time_frame": "2years"
        }, 
        "source": "Peking University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Peking University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Endpoint Classification: Bio-equivalence Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "May 2013"
    }
}